Compounds and compositions for intracellular delivery of therapeutic agents

Patent metadata

Field	Value
Publication number	US-10857105-B2
Application number	US-201916382423-A
Country	US
Kind code	B2
Filing date	Apr 12, 2019
Priority date	Mar 15, 2017
Publication date	Dec 8, 2020
Grant date	Dec 8, 2020

Abstract

The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.

First claim

The invention claimed is:

1. A compound being Compound 301:

or a salt or isomer thereof.

2. The compound of claim 1 , wherein the salt is a pharmaceutically acceptable salt.

3. A nanoparticle composition comprising a lipid component which comprises the compound of claim 1 .

4. The nanoparticle composition of claim 3 , wherein the lipid component further comprises a phospholipid.

5. The nanoparticle composition of claim 4 , wherein the phospholipid is selected from the group consisting of
1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC),
1,2-dimyristoyl-sn-glycero-phosphocholine (DMPC),
1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC),
1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC),
1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC),
1,2-diundecanoyl-sn-glycero-phosphocholine (DUPC),
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC),
1,2-di-O-octadecenyl-sn-glycero-3-phosphocholine (18:0 Diether PC),
1-oleoyl-2-cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine (OChemsPC),
1-hexadecyl-sn-glycero-3-phosphocholine (C16 Lyso PC),
1,2-dilinolenoyl-sn-glycero-3-phosphocholine,
1,2-diarachidonoyl-sn-glycero-3-phosphocholine,
1,2-didocosahexaenoyl-sn-glycero-3-phosphocholine,
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE),
1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine (ME 16.0 PE),
1,2-distearoyl-sn-glycero-3-phosphoethanolamine,
1,2-dilinoleoyl-sn-glycero-3-phosphoethanolamine,
1,2-dilinolenoyl-sn-glycero-3-phosphoethanolamine,
1,2-diarachidonoyl-sn-glycero-3-phosphoethanolamine,
1,2-didocosahexaenoyl-sn-glycero-3-phosphoethanolamine,
1,2-dioleoyl-sn-glycero-3-phospho-rac-(1-glycerol) sodium salt (DOPG), sphingomyelin, and
mixtures thereof.

6. The nanoparticle composition of claim 5 , wherein the phospholipid is DSPC or DOPE.

7. The nanoparticle composition of claim 4 , wherein the lipid component further comprises a structural lipid.

8. The nanoparticle composition of claim 7 , wherein the structural lipid is selected from the group consisting of cholesterol, fecosterol, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, tomatidine, ursolic acid, alpha-tocopherol, and mixtures thereof.

9. The nanoparticle composition of claim 8 , wherein the structural lipid is cholesterol.

10. The nanoparticle composition of claim 7 , wherein the lipid component further comprises a PEG lipid.

11. The nanoparticle composition of claim 10 , wherein the PEG lipid is selected from the group consisting of a PEG-modified phosphatidylethanolamine, a PEG-modified phosphatidic acid, a PEG-modified ceramide, a PEG-modified dialkylamine, a PEG-modified diacylglycerol, a PEG-modified dialkylglycerol, and mixtures thereof.

12. The nanoparticle composition of claim 10 , wherein the lipid component comprises about 30 mol % to about 60 mol % said Compound 301, about 0 mol % to about 30 mol % phospholipid, about 18.5 mol % to about 48.5 mol % structural lipid, and about 0 mol % to about 10 mol % PEG lipid.

13. The nanoparticle composition of claim 10 , wherein the lipid component comprises about 35 mol % to about 55 mol % said Compound 301, about 5 mol % to about 25 mol % phospholipid, about 30 mol % to about 40 mol % structural lipid, and about 0 mol % to about 10 mol % PEG lipid.

14. The nanoparticle composition of claim 10 , wherein the lipid component comprises about 50 mol % said Compound 301, about 10 mol % phospholipid, about 38.5 mol % structural lipid, and about 1.5 mol % PEG lipid.

15. The nanoparticle composition of claim 10 , further comprising a therapeutic and/or prophylactic agent.

16. The nanoparticle composition of claim 12 , further comprising a therapeutic and/or prophylactic agent.

17. The nanoparticle composition of claim 13 , further comprising a therapeutic and/or prophylactic agent.

18. The nanoparticle composition of claim 15 , wherein the therapeutic and/or prophylactic agent is a nucleic acid.

19. The nanoparticle composition of claim 15 , wherein the therapeutic and/or prophylactic agent is a ribonucleic acid (RNA).

20. The nanoparticle composition of claim 19 , wherein the RNA is selected from the group consisting of a small interfering RNA (siRNA), an asymmetrical interfering RNA (aiRNA), a microRNA (miRNA), a Dicer-substrate RNA (dsRNA), a small hairpin RNA (shRNA), a messenger RNA (mRNA), and mixtures thereof.

21. The nanoparticle composition of claim 19 , wherein the RNA is mRNA.

22. The nanoparticle composition of claim 21 , wherein the mRNA includes one or more of a stem loop, a chain terminating nucleoside, a polyA sequence, a polyadenylation signal, and/or a 5′ cap structure.

23. The nanoparticle composition of claim 15 , wherein the encapsulation efficiency of the therapeutic and/or prophylactic agent is between 80% and 100%.

24. The nanoparticle composition of claim 21 , wherein the wt/wt ratio of the lipid component to the mRNA is from about 10:1 to about 60:1.

25. The nanoparticle composition of claim 21 , wherein the wt/wt ratio of the lipid component to the mRNA is about 20:1.

26. The nanoparticle composition of claim 21 , wherein the N:P ratio is from about 5:1 to about 8:1.

27. A pharmaceutical composition comprising the nanoparticle composition of claim 21 and a pharmaceutically acceptable carrier.

28. A method of delivering a prophylactic agent to a mammalian cell within a mammalian subject, the method comprising administering to the mammalian subject the nanoparticle composition of claim 15 wherein the nanoparticle composition comprises the prophylactic agent, to contact the mammalian cell with the prophylactic agent, whereby the prophylactic agent is delivered to the mammalian cell.

29. A method of producing a polypeptide of interest in a mammalian cell, the method comprising contacting the cell with the nanoparticle composition of claim 21 , wherein the mRNA encodes the polypeptide of interest, whereby the mRNA is translated in the cell to produce the polypeptide of interest.

30. A method of treating a disease or disorder in a mammal in need thereof, the method comprising administering to the mammal a therapeutically effective amount of the nanoparticle composition of claim 15 .

Assignees

• Modernatx Inc
• Mordernatx Inc

Inventors

• Benenato Kerry E
• Kumarasinghe Ellalahewage Sathyajith
• Cornebise Mark

Classifications

• C07D233/64

  with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine · CPC title

• C07C237/24

  having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton · CPC title

• C07C219/20

  the carbon skeleton being unsaturated · CPC title

• C07C219/06 Primary

  having the hydroxy groups esterified by carboxylic acids having the esterifying carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms of an acyclic saturated carbon skeleton · CPC title

• A61K47/28

  Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid · CPC title